跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
辅舒酮 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Fluticasone Propionate Inhalation Aerosol
Approved
化学药品
Fluticasone Propionate Inhalation Aerosol
Glaxosmithkline Australia Pty Ltd.
🇨🇳 National Medical Products Administration
Approval Date
Dec 27, 2019
Approval ID
7MazXcUZi5o
Company
Glaxosmithkline Australia Pty Ltd.
Type
化学药品
Approval Details
Approval Id
7MazXcUZi5o
Approval Number
H20130189
Generic Name
丙酸氟替卡松吸入气雾剂
Generic Name En
Fluticasone Propionate Inhalation Aerosol
Trade Name
辅舒酮
Brand Name
辅舒酮
Drug Type
化学药品
Dosage Form
吸入气雾剂
Strength
每瓶120揿,每揿含丙酸氟替卡松50μg,递送剂量为丙酸氟替卡松44μg
Reg Date
2019-12-27
Expired Date
2023-12-20
Company Name
Glaxosmithkline Australia Pty Ltd.
Company Address
Level 4/436 Johnston Street ABBOTSFORD VIC 3067 AUSTRALIA
Production Company Name
Glaxo Wellcome SA
Production Company Address
Avda de Extremadura 3 Poligono Industrial Allenduero Aranda De Duero, Burgos, 09400 Spain
Company Detail Path
/organization/glaxosmithkline-australia-pty-ltd-australia
Production Company Detail Path
/organization/glaxo-wellcome-sa
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 27, 2019
Approval ID
7MazXcUZi5o
Type
化学药品
Back to NMPA Approvals